Albertsen to discuss “contemporary recommendations” on AS at AUA annual meeting

In one of the more important lectures at the upcoming annual meeting of the American Urological Association, starting in Orlando in a couple of weeks’ time, Dr. Peter Albertsen will be reviewing contemporary recommendations on the practice of active surveillance (AS) for men with low- and very low-risk prostate cancer. … READ MORE …

One man’s route to active surveillance as a first-line management strategy

When CT learned that he had low-grade, organ-confined prostate cancer, he did not decide to get surgical or other therapeutic interventions immediately, based on the guidance of the first doctors he saw. Instead, he decided to actively monitor his disease and adjust his lifestyle habits with guidance from a team of specialists. … READ MORE …

How active should “active surveillance” really be? Are we being overly cautious?

There are a couple of brief but interesting new articles about active surveillance by Dr. Oliver Sartor and Laurence Klotz on the CancerNetwork.com web site this week. They deal with differing perceptions about the application of active surveillance. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

What happened early this morning at the GU Cancers Symposium

So … as a couple of readers have already realized … the sheer quantity of new and interesting data at the meeting is enormous, and your reporter is going to have to select what he tries to covers with care, ‘cos there’s no way to cover it all! … READ MORE …

New point of care PSA test … coming soon to your doctor’s office?

According to a media release issued last week by a relatively new company called True Diagnostics, Inc., they hope shortly to be able to introduce a new, “point of care” technical system that can be used to assay PSA levels from a “finger-prick” quantity of blood, thus allowing almost instant assessment of PSA levels in the doctor’s office. … READ MORE …

30 years follow-up of men with initially untreated, localized prostate cancer

A new article in European Urology offers interesting data on the natural history of localized prostate cancer, based on a cohort of 200+ Swedish patients followed for > 30 years. It is important to note immediately that none of these men was originally diagnosed in the PSA era. They all had some form of symptomatic disease at diagnosis. … READ MORE …

National Proactive Surveillance Network goes live in Baltimore and Los Angeles

As reported previously, in May 2010, the Prostate Cancer Foundation, in association with Johns Hopkins and the Cedars-Sinai Medical Center announced their intention to develop a national initiative to track the management of men with prostate cancer using active monitoring  (“active surveillance”) as opposed to invasive treatment. … READ MORE …

Speciality bias still affecting treatment recommendations for low-risk prostate cancer?

A majority of urologists and radiation oncologists are still not recommending active monitoring (“active surveillance”) as a first-line method for the management of patients with low-risk prostate cancer. … READ MORE …

The scientific basis for PSA monitoring after first-line treatment for localized prostate cancer

A new article in the Canadian Medical Association Journal has reported on a careful analysis of the published literature underlying current guidelines on the use of repetitive PSA testing to monitor risk for progression in men receiving first-line treatment for localized prostate cancer. … READ MORE …

3 Tesla MRI imaging and the diagnosis of localized prostate cancer

It has been noted previously in this blog that we are improving our ability to accurately identify localized prostate cancer using several types of imaging technology. … READ MORE …

PSA monitoring after prostate cancer surgery: how long is long enough?

A paper currently “in press” in the Journal of Urology suggests that annual PSA testing “may be safely discontinued after 10 years for men with a prostatectomy Gleason score 6 or less and/or limited life expectancy.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,113 other followers